欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (10): 1131-1138.doi: 10.12092/j.issn.1009-2501.2020.10.008

• 药物治疗学 • 上一篇    下一篇

DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响

闫盼1,施剑飞2,李静1,王晟东1,王姝琪1,汪程鹏2,宋明芬1   

  1. 1杭州市第七人民医院分子生物学实验室,2杭州市第七人民医院精神科,杭州 310013,浙江
  • 收稿日期:2020-05-06 修回日期:2020-09-10 出版日期:2020-10-26 发布日期:2020-11-03
  • 通讯作者: 宋明芬,女,博士,副主任医师,研究方向:常见精神疾病的分子机制研究。 Tel: 0571-87356717 E-mail: songmingfen2005@163.com
  • 作者简介:闫盼,女,硕士,住院医师,研究方向:抗精神分裂症药物基因组学研究。 Tel: 18458186402 E-mail: bzyxyyanpan@163.com
  • 基金资助:
    浙江省医药卫生科技计划项目(2020KY222,2020KY744);浙江省科技厅重点研发计划项目(2015C03054)

Effects of DRD2 and 5-HTR2A gene polymorphisms and their interaction on olanzapine in the treatment of schizophrenia

YAN Pan 1, SHI Jianfei 2, LI Jing 1, WANG Shengdong 1, WANG Shuqi 1, WANG Chengpeng 2, SONG Mingfen 1   

  1. 1 Department of Molecular Biology Laboratory, Hangzhou Seventh People's Hospital; 2 Department of Geriatric Psychiatry, Hangzhou Seventh People's Hospital, Hangzhou 310013, Zhejiang, China
  • Received:2020-05-06 Revised:2020-09-10 Online:2020-10-26 Published:2020-11-03

摘要: 目的:探讨多巴胺D2受体(dopamine D2 receptor, DRD2)和5-羟色胺2A受体(5-hydroxytryptamine 2A receptor, 5-HTR2A)基因多态性及其交互作用与奥氮平治疗精神分裂症疗效的关系。方法:纳入147例接受单一奥氮平治疗的精神分裂症住院患者为研究对象,采用阳性与阴性症状量表(PANSS)评定药物疗效,按PANSS减分率≥50%和<50%,分为有效组和无效组。采用多重高温连接酶检测反应技术(iMLDR)检测DRD2(rs1799978、rs1800497)和5-HTR2A(rs6311、rs6313)基因多态性;采用多因素Logistic回归分析各基因型和奥氮平疗效的关联性,采用多因子降维法(MDR)分析基因-基因的交互作用。结果:有效组和无效组rs1799978、rs6313位点基因型和等位基因频率分布差异均有统计学意义(P<0.05),而两组rs1800497、rs6311位点基因型和等位基因频率分布差异均无统计学意义(P>0.05);rs1799978位点GA和GG型患者奥氮平疗效较野生AA型好,其比值比(OR)及95%CI分别为5.101(1.118~23.267)、6.051(2.454~14.925);rs6313位点CT和CC型患者奥氮平疗效较野生TT型好,其OR及95%CI分别为2.623(1.054~6.528)、3.412(1.180~9.869);rs1799978、rs1800497和rs6313位点间存在交互作用,其交互模型为最优基因-基因交互作用模型(P<0.05),该模型检验样本准确度为0.727 3,交叉验证一致性为10/10。结论:DRD2(rs1799978)和5-HTR2A(rs6313)基因多态性可能与奥氮平治疗精神分裂症疗效相关,DRD2(rs1799978、rs1800497)和5-HTR2A(rs6313)对奥氮平疗效的影响存在交互作用。

关键词: 精神分裂症, 奥氮平, 多巴胺D2受体, 5-羟色胺2A受体, 基因多态性, 基因-基因交互作用, 临床疗效

Abstract: AIM: To investigate the association of dopamine D2 receptor (DRD2) and 5-hydroxytryptamine 2A receptor (5-HTR2A) gene polymorphisms and their interactions with efficacy of olanzapine in treatment of schizophrenic patients.  METHODS: A total of 147 schizophrenic patients who treated with olanzapine alone were recruited. The positive and negative symptom scale (PANSS) was used to evaluate the efficacy of drugs. According to PANSS reduction rate ≥50% and <50%, patients were divided into the effective group and the ineffective group. The gene polymorphisms of DRD2 (rs1799978, rs1800497) and 5-HTR2A (rs6311, rs6313) were detected by improved multiple ligase detection reaction (iMLDR). Multivariate Logistic regression analysis was used to analyze the correlation between genotypes and olanzapine efficacy, and multifactor dimensionality reduction (MDR) was used to analyze gene-gene interactions. RESULTS: There were significant differences in genotype and allele frequencies of rs1799978 and rs6313 between the effective group and the ineffective group (P<0.05), while there was no difference in genotype and allele frequencies of rs1800497 and rs6311 (P<0.05). Patients with GA and GG of rs1799978 locus were more effective than those with wild type AA when treated with olanzapine, and the ORs (95%CI) were 5.101 (1.118-23.267) and 6.051 (2.454-14.925), respectively. Patients with CT and CC of rs6313 locus were more effective than those with wild type TT when treated with olanzapine, and the ORs (95%CI) were 2.623 (1.054-6.528) and 3.412 (1.180-9.869), respectively. There was a interaction between the gene polymorphisms of rs1799978, rs1800497 and rs6313. The interaction model was the optimal gene-gene interaction model (P<0.05) with the verify sample accuracy rate of 0.727 3 and a cross-validation consistency of 10/10. CONCLUSION: The gene polymorphisms of DRD2 (rs1799978) and 5-HTR2A (rs6313) may be associated with efficacy of olanzapine in treatment of schizophrenic patients, and there is a interaction between DRD2 (rs1799978, rs1800497) and 5-HTR2A (rs6313) on the efficacy of olanzapine.

Key words: schizophrenia, olanzapine, DRD2, 5-HTR2A, gene polymorphism, gene-gene interaction, therapeutic effects

中图分类号: